Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

188.12
-12.7500-6.35%
Post-market: 188.05-0.0700-0.04%17:54 EDT
Volume:4.86M
Turnover:903.21M
Market Cap:40.32B
PE:-21.09
High:199.64
Open:198.51
Low:180.49
Close:200.87
52wk High:224.31
52wk Low:46.16
Shares:214.34M
Float Shares:185.00M
Volume Ratio:3.07
T/O Rate:2.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:15.47
PE(LYR):-31.62

Loading ...

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live
·
Aug 27

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live
·
Aug 27

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS
·
Aug 27

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
Aug 27

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Dow Jones
·
Aug 26

Movement Alert|Revolution Medicines, Inc. Falls 5.34% in Regular Trading, Trading at $200.13

Market Focus
·
Aug 26

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Aug 26

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 26

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million

Reuters
·
Aug 26

Revolution Medicines, Inc. : Bernstein Raises Target Price to $179 from $151

THOMSON REUTERS
·
Aug 21

Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD

TIPRANKS
·
Aug 21

Movement Alert|Revolution Medicines, Inc. Rises 5.05% in Regular Trading, BeiGene RAS Inhibitor Collaboration Continues to Drive Momentum

Market Focus
·
Aug 18

Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal

Reuters
·
Aug 13

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

GlobeNewswire
·
Aug 12

Revolution Medicines Price Target Raised to $231.00/Share from $210.00 by Truist Securities

Dow Jones
·
Aug 12